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Abstract
Introduction: Rheumatoid arthritis (RA) patients with structural progression are in most need of immediate
treatment to maintain tissue integrity. The serum protein fingerprint, type I collagen degradation mediated by
matrix metalloproteinases (MMP)-cleavage (C1M), is a biomarker of tissue destruction. We investigated whether
baseline serum C1M levels could identify structural progressors and if the biomarker levels changed during anti-
inflammatory treatment with tocilizumab (TCZ).
Methods: The LITHE-biomarker study (NCT00106535, n = 585) was a one-year phase III, double-blind, placebo
(PBO)-controlled, parallel group study of TCZ 4 or 8 mg/kg every four weeks, in RA patients on stable doses of
methotrexate (MTX). Spearman’s ranked correlation was used to assess the correlation between baseline C1M levels
and structural progression at baseline and at weeks 24 and 52. Multivariate regression was performed for delta
structural progression. Change in C1M levels were studied as a function of time and treatment.
Results: At baseline, C1M was significantly correlated to C-reactive protein (P <0.0001), visual analog scale pain
(P <0.0001), disease activity score28-erythrocyte sedimentation rate (DAS28-ESR) (P <0.0001), joint space narrowing
(JSN) (P = 0.0056) and modified total Sharp score (mTSS) (P = 0.0006). Baseline C1M was significantly correlated
with delta-JSN at Week 24 (R2 = 0.09, P = 0.0001) and at Week 52 (R2 = 0.27, P <0.0001), and with delta-mTSS at
24 weeks (R2 = 0.006, P = 0.0015) and strongly at 52 weeks (R2 = 0.013, P <0.0001) in the PBO group. C1M levels
were dose-dependently reduced in the TCZ + MTX group.
Conclusions: Baseline C1M levels correlated with worsening joint structure over one year. Serum C1M levels may
enable identification of those RA patients that are in most need of aggressive treatment
Trial registration: ClinicalTrials.gov: NCT00106535
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Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease characterized by inflammation and massive tissue
destruction in multiple synovial joints. Aggressive treat-
ment for patients whose disease is rapidly progressing
(progressors) may preserve joint function. However, it is
very difficult using standard technologies to identify pro-
gressors. Identification of progressors is also important
as most anti-inflammatory treatments are associated
with side effects emphasizing that only those who are in
most need of aggressive treatment (that is, progressors)
should be appropriately treated, which may improve the
benefit-risk ratio of these therapies.
In RA, the periarticular bone and cartilage undergo
major destructive changes, whereas the altered turnover
of the synovial membrane results in an expansion of the
synovial membrane. The extracellular matrix (ECM) is
the most prominent component of these tissues and the
most abundant ECM protein is type I collagen. However,
type II collagen is the most abundant protein in cartilage
and the most investigated collagen with arthritides.
Destruction of the ECM is mediated by enzymatic clea-
vage by different proteases, though predominantly by
matrix metalloproteinases (MMPs). MMPs have been
shown to be highly up-regulated with RA [1-3] and the
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tissue destruction with specific MMPs elevated with dis-
ease is a central player in inflammatory disease, such as
RA [3,4]. The action of MMPs on ECM results in the
release of small protein ‘fingerprints’ into the circulation,
which may be used as markers of tissue destruction [5,6].
It seems reasonable to hypothesize that connective tissue
destruction mediated by MMPs could be associated with
disease progression in RA.
Type I collagen can be degraded by several proteinases
and in the process yields various products, namely CTX-I,
ICTP, PINP and C1M (Figure 1). CTX-I is a measurement
of Cathepsin K-mediated destruction of type I collagen
and is the standard measure for bone resorption [7]. ICTP
is a triple cross-linked carboxyterminal telopeptide of type
I collagen generated by MMPs and destroyed by Cathepsin
K and, therefore, not related to bone type I collagen [7,8].
Lastly, PINP is widely used as a measure of type I collagen
formation in bone [9-12].
We recently developed and validated an enzyme-linked
immunosorbent assay (ELISA) using a monoclonal anti-
body detecting a degradation fragment of the helical
domain of type I collagen mediated by MMP-cleavage
and destroyed by Cathepsin K (C1M) [13]. This ELISA
does not recognize intact type I collagen, other collagens,
or the products of other proteinase-mediated collagen
degradation. C1M is a product of MMP-2, -9 and -13
cleavage of type I collagen, but not MMP-3, -8 or Cathe-
psin K cleavage. Therefore, C1M is not a biomarker of
hard tissue (that is, bone), but a biomarker of soft tissue
destruction, due to the destruction of the fragment by
Cathepsin K. Therefore, it represents another pool of
type I collagen degradation than PINP, CTX-I and ICTP,
namely, exclusively MMP-mediated connective tissue
destruction [13].
The aim of the present study was to investigate
whether MMP-mediated type I collagen destruction,
measured by serum levels of C1M, could be a novel bio-
chemical marker for identification of progressors in RA.
We investigated whether baseline levels of serum C1M
were correlated with structural status and progression of
RA, by measuring change in joint space narrowing, total
Sharp score and erosion, in the placebo group of the bio-
marker study of the LITHE study [14]. We, furthermore,
investigated whether serum C1M levels were altered fol-
lowing treatment of RA with an anti-IL-6R monoclonal
antibody, tocilizumab (TCZ), in combination with meth-
otrexate (MTX) in the biomarker study in the LITHE
study [14,15]. Lastly, we investigated if the change in
C1M at four weeks was related to change in one year
radiographic measures and if including the standard bio-
marker (C-reactive protein, CRP) of RA increased the
predictive value of C1M.
Material and methods
LITHE study
The LITHE Biomarker study formed part of the LITHE
study (ClinicalTrials.goc: NCT00106535), which was a
two-year phase III, double-blind, placebo-controlled, par-
allel group study of TCZ (4 mg/kg or 8 mg/kg every four
weeks) + MTX (10 to 25 mg/week) in patients with mod-
erate to severe active RA with an inadequate response to
MTX. RA was diagnosed according to the American Col-
lege of Rheumatology criteria [16], and had to have lasted
for six or more months before entering the study. More-
over, the patients had to have radiographically confirmed
joint erosion.
The LITHE Biomarker study included 585 patients
followed for the first 52 weeks from baseline. Biomarker
patients were equally distributed among the treatment
groups; placebo (PBO; n = 199), 4 mg/kg TCZ (TCZ4;
n = 200) and 8 mg/kg TCZ (TCZ8; n = 186). Stable
non-steroidal anti-inflammatory drugs and corticoster-
oid (≤10 mg/day prednisone or equivalent) doses were
continued throughout the study. Every 4 weeks, patients
received an infusion of TCZ 4 mg/kg, 8 mg/kg, or pla-
cebo for a total of up to 13 infusions in 52 weeks.
Serum for biomarker research was collected following
overnight fasting at baseline, at weeks 4, 16, 24 and 52
and non-fasted at Week 2. All samples were stored
below -70°C until assay.
Patients who failed to respond to treatment during the
study, that is, experienced ≤20% improvement from
Figure 1 Biochemical markers of type I collagen. PINP, Pro-collagen type I N-terminal pro-peptide; C1M, MMP-degraded type I collagen. The
C1M peptide is located at amino acid position 755 to 764 in the mature collagen strands. ICTP, Pyridinoline cross-linked carboxyterminal
telopeptide of type I collagen. CTX-I, cross-linked c-telo-peptide of type I collagen at amino acid position 1207 to 1214.
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baseline in both swollen (SJC) and tender joint counts
(TJC) at Week 16, could receive blinded rescue therapy
from Week 16, and subsequently, 12 weeks later (at
Week 28) if there was still ≤20% improvement. First-
step rescue patients receiving PBO + MTX switched at
Week 16 to TCZ 4 mg/kg + MTX. Patients receiving
4 mg/kg TCZ + MTX switched to 8 mg/kg + MTX and
patients on 8 mg/kg + MTX discontinued treatment.
Second-step rescue at Week 28 consisted of TCZ
8 mg/kg + MTX, which were offered through to Week
52 if inadequate response persisted after three doses of
first-step rescue therapy. Patients who did not respond
after three doses of second-step rescue discontinued
treatment. The patients from the PBO + MTX group,
who received rescue therapy, were designated escapers.
Half of the patients receiving PBO + MTX at baseline
were receiving first step rescue therapy at Week 52.
Only six patients were on second step rescue therapy at
Week 52 (Figure 2).
Radiographs of hands and feet were obtained at base-
line, Week 24 and Week 52. Radiographs were assessed
with joint space narrowing (JSN), the total Genant-
modified Sharp scoring system (mTSS) [17] and erosion
by two independent readers, who were blinded to treat-
ment assignment, chronological order of radiographs
and patients’ clinical responses. The average score of the
two readers was used in the analysis. The visual analog
scale of pain (VAS) and disease activity score-28-
erythrocyte sedimentation rate (DAS28-ESR) were assessed
at baseline, and at weeks 24 and 52. The self-reported gen-
eral health was assessed by the Health Assessment Ques-
tionnaire (HAQ) at baseline, weeks 24 and 52.
The LITHE study was approved by ethical committees
at each participating institution [14]. All patients in the
LITHE study provided written informed consent.
According to Danish law, it is not required to get ethical
approval when measuring biochemical markers in pre-
viously collected samples, hence, there was no ethical
approval for this particular study of C1M in the LITHE
serum samples. The study was conducted according to
the Principal of Good Clinical Practice and according to
the Declaration of Helsinki.
Biochemical markers
CRP was quantified in patients at baseline, 24 and
52 weeks. C1M was measured in samples taken at baseline
and at weeks 2, 4, 16, 24 and 52 using the newly developed
C1M ELISA assay (11), which is based on a monoclonal
antibody recognizing the fragment GSPGKDGVRG at
position 764 in the mature type I collagen.
Statistics
Summary statistics were used for general demographics,
baseline RA characteristics and baseline American College
of Rheumatology demographics. Spearman’s ranked corre-
lation was conducted on baseline level of serum C1M, age,
body mass index (BMI), disease duration, VAS pain,
DAS28-ESR, HAQ, JSN and mTSS. The same correlation
test was applied to compare baseline C1M with change in
CRP, VAS pain, HAQ, DAS28-ESR, JSN and mTSS at
weeks 24 and 52.
Multiple regression analysis was performed on log-trans-
formed data for delta structural progression (JSN, mTSS
and erosion score) and C1M, with the cofounders age,
BMI, disease duration, baseline CRP and baseline struc-
tural status.
Changes from baseline in serum C1M levels were studied
as a function of time and treatment. Differences between
the levels of serum C1M at each time point were compared
by two-way ANOVA. The level of change from baseline in
C1M for escape patients and non-escape patients in the
PBO groups was assessed by two-way ANOVA.
To test if CRP increased the predictive value of C1M to
predict progression, high and low levels of C1M and CRP
were determined as higher and lower the respective med-
ian. This provided four groups: 1: High C1M and high
CRP, 2: High C1M and low CRP, 3: Low C1M and high
CRP and 4: low C1M and low CRP. Odds ratio for struc-
tural progression (JSN and mTSS) were assessed between
group 4 and the other groups. The odds ratio for C1M
alone was furthermore determined.
Results
Patient demographics at baseline
A total of 585 patients were included at baseline and
baseline characteristics are listed in Table 1. Of the 199
Figure 2 Study design of the PBO + MTX group (n = 199) in the
LITHE biomarker study. Patients with <20% improvement (escape
patients) at Week 16 were given 4 mg/kg TCZ + MTX every four weeks
from Week 16. At Week 28 PBO + MTX patients who had received
4 mg/kg TCZ + MTX were evaluated and patients with <20% were
given 8 mg/kg TCZ + MTX every four weeks. Responders to TCZ
(>20% improvement) remained on 4 mg/kg TCZ + MTX for the rest of
the study. If patients who went on to 8 mg/kg TCZ + MTX did not
respond after three doses, they were excluded from the remainder of
the study, but were included in the Week 24 analysis. Dashed line: First
rescue therapy. Dotted line: Second stage rescue therapy. MTX,
methotrexate; PBO, placebo; TCZ, tocilizumab
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patients in the PBO + MTX group 109 patients received
rescue at Week 16. The percentage of women in the study
was 83%. At baseline, the mean age of the biomarker
study population was 51.6 years (SD: 12.6), mean BMI was
28.1 kg/m2 (SD: 7.4) and mean disease duration was 9.3
years (SD: 8.2). The mean HAQ score was 1.54 (SD: 0.61)
and mean VAS pain was 54.8 (SD: 21.3). Mean DAS28-
ESR was 6.5 (SD: 0.98), mean JSN was 11.6 (SD: 15.7),
mean mTSS was 27.9 (SD: 32.3) and mean erosion score
was 16.6 (SD: 16.3). The mean CRP was 2.15 mg/dL (SD:
2.52) and C1M was 109 nmol/L (SD: 72).
Univariate analysis
Baseline C1M was not correlated to age, BMI or disease
duration (Table 2). Baseline C1M was highly correlated to
delta serum CRP in all groups at both weeks 24 and 52
(Table 2). At baseline, C1M was positively correlated to
baseline CRP (r = 0.8), but at 24 and 52 weeks it was
negatively correlated, r = -0.31 and r = -0.36, respectively.
C1M at baseline was significantly correlated to VAS pain
(r = 21, P <0.0001), HAQ (r = 0.21, P <0.0001), DAS28-
ESR (r = 0.25, P <0.0001) and JSN (r = 0.12, P = 0.0056).
Delta-VAS pain, delta-HAQ, delta-DAS28-ESR and delta
JSN were not significantly correlated to baseline C1M at
either 24 or 52 weeks in the total PBO + MTX population
or the w/o-escape PBO + MTX population.
At baseline, C1M was significantly correlated to mTSS
(r = 0.14, P = 0.0006). At 24 weeks, when a proportion
of the PBO group was receiving rescue treatment, there
was a significant correlation between baseline C1M and
delta-mTSS (r = 0.19, P = 0.017). However, this correla-
tion was stronger when patients receiving rescue treat-
ment (n = 109) were excluded from the analysis (r =
0.28, P = 0.0084). At Week 52 there was an even stron-
ger correlation between delta-mTSS and baseline C1M
(r = 0.34, P = 0.0017) in the patients of the PBO +
MTX group not receiving rescue therapy.
Multiple regression analysis
The effect size of C1M was b = 0.34, b = 1.13 and b =
0.79 for the association with the change in structural
progression as determined by JSN, mTSS and erosion
score at Week 24, respectively. A higher effect size was
seen at Week 52 with b = 1.38, b = 3.40 and b = 2.01,
respectively. A b-value illustrates the effect of a variable
on another variable, meaning that with a little b-value
the covariates do not have an effect on the predicting
value. When b is large, the variable has big effect on the
predicting value.
The significant association increased when CRP was
taken into account at both time points for JSN and mTSS.
For erosion score, the significant association was elimi-
nated. When the other possible cofounders (age, BMI, dis-
ease duration and baseline radiographic score) were
included, a slight decrease was detected at both time
points with JSN, mTSS and erosion scores (Table 3). Inter-
estingly, the effect of the cofounders on mTSS and erosion
score at 24 weeks lowered the b to below the analysis
without the cofounders, making the effect of C1M as pre-
dicting structural progression less significant.
The overall regression models showed more significance
with higher correlation coefficients at Week 52 than Week
24 (Table 3). The model for changes in JSN was strongly
correlated with baseline C1M at both 24 and 52 weeks
(P = 0.0029 and P <0.0001, respectively). The model for
mTSS and erosion at 24 weeks was not correlated with
C1M (P = 0.13 and P = 0.59), but strongly correlated at 52
weeks (P <0.0001 and P = 0.0066).
Odds ratio for structural progression
We investigated whether a combination of high baseline
C1M (>89.28 nmol/L) and high baseline CRP (>1.42
nmol/L) levels was a stronger predictor of disease pro-
gression than C1M alone. Patients with high C1M alone
had a significantly higher odds ratio (95% CI) of radio-
graphic progression with both JSN and mTSS than
patients with low C1M alone (JSN; 3.15 (1.50 to 6.58),
P = 0.0023 and mTSS; 2.94 (1.71 to 5.05), P = 0.0001)
Patients were then categorized according to high or low
baseline C1M and high and low CRP determined by the
median. Patients having both high C1M and CRP had a
significantly higher odds ratio (95% CI) for radiographic
progression than patients with both low C1M and CRP





Age (years) 52.2 12.3
BMI (kg/m2) 27.4 6.1
Disease duration (years) 9.4 8.1
Disease parameters
HAQ 1.51 0.62
VAS pain 54.4 22.1
TJC (n) 28 16






CRP (mg/L) 2.13 2.57
C1M (nmol/L) 109 72.0
BMI, Body mass index; CRP, C-reactive protein; DAS28-ESR, Disease activity
score 28-ESR; ERN, Erosion score; HAQ, Health assessment questionnaire; JSN,
joint space narrowing; mTSS, modified total Sharp score; SJC, Swollen joint
count; TJC, Tender joint count; VAS, Visual analog scale of pain
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(JSN; 3.55, (1.97 to 6.41), P <0.0001 and mTSS; 3.6,
(1.62 to 8.08), P = 0.0018); Table 4). Patients with a
combination of high and low biomarkers had only slight
but not significantly higher odds for radiographic pro-
gression than patients with both low C1M and CRP. Of
those patients with both high C1M and CRP, 18% and
34% had radiographic progression by JSN and mTSS,
respectively. Only 13% and 6% of patients with both low
C1M and CRP had radiographic progression read by
JSN and mTSS, respectively. Hence, also testing for CRP
level increases the odds ratio from 3.15 and 2.94 to 3.61
and 3.55 for JSN and mTSS, respectively.
Dose-dependent response
Patients receiving 4 mg/kg TCZ + MTX had a rapid
decrease (in the first two weeks) in C1M levels of 49.6%
from baseline. However, this effect disappeared at Week
4 and was not significantly different from the C1M
levels seen in the PBO + MTX group (Figure 3A). The
C1M fragment was detected at a lower level in the
4 mg/kg TCZ + MTX group than the PBO + MTX
group at Week 16 (21.6%, P >0.05), 24 (22.4%, P <0.01),
and 52 (12.5%, P <0.05). The 8 mg/kg TCZ + MTX
group had significantly lower levels of C1M after treat-
ment compared with the PBO + MTX group (Figure 3A).
A rapid decrease in C1M was detected at Week 2
(49.2% lower than at baseline, P <0.0001), as was seen in
the 4 mg/kg TCZ + MTX group. The level of C1M
remained at a significantly lower level in the 8 mg/kg
TCZ + MTX than in the PBO group throughout the
study (P <0.0001), although C1M levels increased
slightly with time.
Table 2 Univariate correlation between clinical markers and baseline serum C1M




r P N r P n r P n r P n
Age -0.06 ns 585 - - - - - - - - -
BMI 0.01 ns 578 - - - - - - - - -
Disdur -0.01 ns 584 - - - - - - - - -
CRP 0.80 <0.0001 584 -0.31 0.001 112 -0.31 0.0023 93 -0.36 0.0007 83
VAS pain 0.21 <0.0001 578 -0.08 ns 110 -0.05 ns 91 -0.00 ns 83
HAQ 0.21 <0.0001 535 -0.17 ns 98 -0.15 ns 82 -0.11 ns 76
DAS28 0.24 <0.0001 573 0.09 ns 108 0.15 ns 89 0.11 ns 77
JSN 0.12 0.0056 556 0.08 ns 153 0.16 ns 90 0.21 0.055 84
mTSS 0.14 0.0006 556 0.19 0.017 153 0.28 0.0084 90 0.34 0.0017 84
ERN 0.15 0.0003 556 0.19 0.019 153 0.13 ns 90 0.21 0.054 84
BMI, Body mass index; DisDur, Disease duration;CRP, C-reactive protein; DAS28-ESR, Disease activity score 28-ESR; HAQ, Health assessment questionnaire; JSN,
Joint space narrowing; mTSS, modified total Sharp score; PBO, placebo group; VAS pain, Visual analog scale of pain. Spearman rank correlation coefficient r, the
P-values and n are provided.
Table 3 Multivariate linear regression analysis of patients in the PBO group, at 24 and 52 weeks.
Δ24 weeks Δ52 weeks
JSN b P R2 n b P R2 n
C1M 0.34 0.013 0.04 153 1.38 0.0015 0.11 85
C1M adjusted for CRP 0.74 0.0013 0.06 153 3.91 <0.0001 0.27 85
C1M adjusted for CRP, age, BMI and disease duration 0.69 0.0022 0.11 151 3.60 <0.0001 0.30 83
C1M adjusted for CRP, age, BMI, disease duration and baseline JSN 0.68 0.0029 0.11 151 3.55 <0.0001 0.31 83
mTSS
C1M 1.13 0.0035 0.05 153 3.40 0.0001 0.17 85
C1M adjusted for CRP 1.17 0.07 0.04 153 7.13 <0.0001 0.25 85
C1M adjusted for CRP, age, BMI and disease duration 0.98 0.11 0.14 151 6.12 <0.0001 0.32 83
C1M adjusted for CRP, age, BMI, disease duration and baseline mTSS 0.95 0.13 0.14 151 6.04 <0.0001 0.32 83
ERN
C1M 0.79 0.009 0.038 153 2.01 0.0002 0.15 85
C1M adjusted for CRP 0.43 0.39 0.037 153 3.22 0.0006 0.17 85
C1M adjusted for CRP, age, BMI and disease duration 0.29 0.56 0.12 151 2.52 0.0055 0.25 83
C1M adjusted for CRP, age, BMI, disease duration and baseline ERN 0.26 0.59 0.12 151 2.47 0.0066 0.25 83
BMI, Body mass index; C1M, Type I collagen degraded by MMPs; CRP- C-reactive protein; ERN, erosion score; JSN, joint space narrowing; mTSS, modified total
Sharp score. The regression coefficient, b, P-value and R2 are given. Data were log-transformed before analysis.
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To further study the effect of TCZ on C1M levels, the
PBO group was separated into escape and non-escape
patients (Figure 2). The mean level of C1M at Week 16
was reduced by 18.2% from baseline in the non-escape
patients, whereas the mean level was 1% of baseline in
the escape patients. The difference in mean level of
C1M between escapers and non-escapers was not signif-
icant (P >0.05). The change from baseline in C1M levels
was similar (approximately 6% decrease) in the escape
and non-escape patients in the PBO group at Week 24,
when the escape patients had been treated with 4 mg/kg
TCZ + MTX for eight weeks (Figure 3B). At Week 52
the level of C1M was significantly higher (P <0.05) in
the non-escape patients than in the escape patients, the
latter of which was treated with either 4 or 8 mg/kg
TCZ (Figure 3B).
Change in C1M at 16 weeks correlated to change in
radiographic measures at 52 weeks in response to TCZ
We investigated whether change in C1M after 16 weeks
in response to 4 or 8 mg/kg TCZ was related to change
in radiographic change after 52 weeks. We separated
patients into two groups, those with less than 35%
change in C1M from baseline to 16 weeks and those
with more than 35% change. A significant difference
was found in change in JSN after 52 weeks between the
two groups (P = 0.035, Figure 4A). A similar difference
was seen for mTSS changes (P = 0.045, Figure 4B).
No difference in erosion was found at either 24 or
52 weeks. There was no change at 24 weeks with JSN
and mTSS.
Discussion
RA is a complex disease in which progression is very
heterogeneous and non-continuous, in which flares may
be important drivers of severe progression. Selecting the
patients who will benefit from a specific treatment
would be an advantage in inflammatory arthritis diseases
in particular, as most, if not all, anti-inflammatory treat-
ments are associated with severe, but manageable, side
effects. In this study we investigated if a novel assay
detecting a protein fingerprint of type I collagen degra-
dation could be a novel biochemical marker for identifi-
cation of progressors in RA. We also investigated the
change in serum C1M levels following treatment with
TCZ and the predictive value of C1M in combination
with CRP. We found that 1) C1M levels were associated
with disease progression, 2) C1M levels were correlated
Table 4 Odds ratios for radiographic progression when combining high and low level of C1M and CRP
C1M/CRP High/High vs. Low/Low High/Low vs. Low/Low Low/High vs. Low/Low Only C1M
JSN OR 3.61 2.37 1.95 3.15
95% CI 1.62 to 8.01 0.59 to 9.44 0.39 to 9.77 1.50 to 6.58
P 0.0018 0.22 0.42 0.0023
mTSS OR 3.55 1.79 1.94 2.94
95% CI 1.97 to 6.41 0.60 to 5.33 0.58 to 6.49 1.71 to 5.05
P <0.0001 0.30 0.28 0.0001
The high and low levels of the biomarkers were based on the median value of all patients at baseline. C1M, Type I collagen degraded by MMPs; CI, confidence
interval; CRP- C-reactive protein; JSN, joint space narrowing; mTSS, modified total Sharp score; OR, odds ratio
Figure 3 C1M levels in PBO + MTX or TCZ + MTX treated patients. A: Percentage change in C1M levels from baseline in all patients
(including patients, who received TCZ). TCZ4, TCZ 4 mg/kg. TCZ8, TCZ 8 mg/kg. B: C1M levels in the subpopulations of the PBO group. Non-
escape Week 16 n = 86, escape Week 16 n = 81. Non-escape Week 24 n = 79, escape Week 24 n = 78, non-escape Week 52 n = 66, escape
Week 52 n = 56. Values are depicted as mean + SEM. Two-way ANOVA test was used to test for differences. Significant levels: *: P <0.05, **: P
<0.01, ****: P <0.0001. C1M, Type I collagen degraded by MMPs; MTX, methotrexate; PBO, placebo; TCZ, tocilizumab
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with disease activity at baseline, 3) baseline C1M was a
significant predictor of structural progression, 4) TCZ
dose-dependently inhibited the level of C1M as early as
two weeks after initiating treatment, and 5) change in
C1M at 16 weeks after treatment initiation was related
to the level of radiographic changes over one year. The
current findings contribute to the literature and the
scientific field by demonstrating that quantifying specific
tissue destruction may aid in selecting the RA patients
in most need of aggressive treatment.
Serological biochemical markers are receiving increased
attention in drug development and for guiding evidence-
based patient management decisions [18]. A range of tra-
ditional markers may provide valuable in managing RA,
such as CRP, ESR, and the interleukins-1 and -6. However,
these markers are systemic biomarkers. A newer class of
molecular biochemical markers, also assessed by simple
ELISA technologies, provides independent and additional
information reflecting structural changes within the tissue
[5]. These markers - protein fragments - are referred to as
protein fingerprints, because they are end results of speci-
fic pathological events, proteolytic degradation of, that is,
the joint structure [5,6]. The protein fingerprint degrada-
tion markers of type I, II and III collagen have been stu-
died and all three have been shown to be descriptive of
disease progression and response to anti-inflammatory
therapy [19]. In this study, we further show that C1M is
highly correlated to CRP levels (Table 2), indicating that
type I collagen degradation in RA is related to inflamma-
tion. Therefore, exploring C1M in RA will indicate the
state of the specific inflammatory structural changes and
not the systemic state of the inflammation. Due to the
relationship between C1M and CRP, we have not investi-
gated the difference between the biomarkers in predicting
progressors of disease.
Interpreting biochemical markers found in serum is
associated with many limitations, as several different tis-
sues at different rates may produce, and thus contribute
to the total pool of, the molecular marker. Type I collagen
is abundant in many tissues throughout the body [5].
Bone in particular may be a prime candidate contributing
to the serological C1M pool as it is naturally being con-
stantly renewed. However, C1M has been shown not to be
correlated with bone metastases, which have high and very
aggressive bone resorption, and, furthermore, not to
recognize MMP-3, -8 and Cathepsin K-cleaved type I col-
lagen [13]. Thus, C1M is a biochemical marker with
increased accuracy for connective tissue turnover. Other
biomarkers of type I collagen degradation have previously
been described in the literature in relation to RA. ICTP, a
C-terminal degradation fragment of the mature type I col-
lagen, has been shown to be related to the severity of RA
[20,21] as well as disease activity [22]. It has been shown
to be useful for assessing the effect of potentially disease
modifying therapies [23]. ICTP in synovial fluid and serum
has been shown to be correlated to radiographic measures
of joint destruction [22,24]. However, RA disease duration
has shown to be a cofounder in ICTP levels [25]. ICTP
has also been described to be correlated to disease activity
in reactive arthritis [26]. Another marker of type I col-
lagen, CTX-I, a marker of Cathepsin K-mediated type I
collagen degradation reflecting bone resorption, has pre-
viously been described to predict disease progression,
albeit only in the worst quartile [27,28]. Furthermore, it
has been shown in a study of early RA patients that CTX-I
at baseline, adjusted for cofounders, was significantly asso-
ciated with radiographic progression in the RA MRI ero-
sion score and classical radiographs over one year [20]. A
drawback of this study, however, was that there was a con-
siderable overlap in CTX-I between progressors and non-
progressors. The same group of investigators has shown
that the relationship between elevated serum levels of
CTX-I and subsequent joint destruction still existed at 10-
year follow-up. However, the relationship was weaker [29].
In the assessment of C1M as a marker of structural pro-
gression in RA, we have utilized radiographic changes
Figure 4 Change in radiographic measures in big/small change in C1M. Change in radiographic measures (JSN and mTSS) after 52 weeks in
patients receiving TCZ with more or less than 35% change in C1M from baseline to 16 weeks. Values are depicted as mean ± 95% CI. Students’
t-test was used to test for differences. Significant levels: *: P <0.05. C1M, Type I collagen degraded by MMPs; JSN, joint space narrowing; MMPs,
matrix metalloproteinases; mTSS, modified total Sharp score; TCZ, tocilizumab
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(JSN, mTSS and erosion score) after 24 and 52 weeks. The
significance level of the correlation between C1M and
radiographic scores was strongest at 52 weeks, especially
with mTSS. This is due to the low sensitivity of the radio-
graphic scores to changes in joints over a short period
[30]. The low sensitivity led to high variation in scores at
24 weeks. The variation decreased when assessing the
radiographic scores at 52 weeks and hence increasing the
statistical power. JSN is a visualization of the space
between the joints and a reduction in JSN indicates loss of
cartilage and meniscal damage, hence only a part on the
JSN could is associated with type I collagen, which partly
could explain the lack of correlation.
A limitation of this study is the effect of concomitant
intake of non-steroidal anti-inflammatory drugs and corti-
costeroid. These medications could have an influence on
the level of C1M, but this contribution cannot be studied
in this setting. Especially, prednisolone intake influences
the level of inflammation and joint damage [31,32]. How-
ever, patients already take stable doses of prednisolone
and/or other drugs at the time they enter the study, hence
the effect of the drugs might be obliterated in the baseline
measurements of C1M. Moreover, the study population of
this investigation has long disease duration at baseline and
profound joint damage, hence the study population is in
an advanced disease stage. It is therefore not a disease
population in which a biomarker of progression is needed.
A study population with shorter disease duration is more
ideal for this type of study. However, the disease progres-
sion of these patients is not as profound and an even lar-
ger study population would be needed. Our present study
aims at identifying progressors of disease by the biomarker
by which this study population is adequate, due to the
rapid progression.
Conclusion
We demonstrated that a simple serum biochemical mar-
ker measurement is able to predict fast progressors in
RA and we also illustrated that C1M could be used as
an efficacy marker. It is critical to effectively treat tissue
destructive diseases, such as RA, early to suppress
inflammation and prevent destruction of the joint.
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